Mergers and Acquisitions

Thermo Fisher’s M&A spend continues with €90m GSK facility

16-May-2019 By Ben Hargreaves

Thermo Fisher announces an agreement that will see it acquire GSK’s Cork manufacturing site.

Takeda divests eye product to Novartis for $5.3bn

09-May-2019 By Ben Hargreaves

Takeda begins the process of divesting products to make its purchase of Shire viable, with $5.7bn worth of assets heading out of the door.

Lundbeck set to add Abide’s chemo-proteomic platform for $400m

06-May-2019 By Ben Hargreaves

Lundbeck announces the acquisition of Abide, which provides the former with access to an R&D platform, a Phase II drug candidate, and drug discovery site in California.

Hired and Retired: Leaving the room

03-May-2019 By Ben Hargreaves

The industry has seen some high profile exits this month, with several individuals vacating, or being asked to vacate, positions on the C-suite.

NEWS IN BRIEF

MS Pharma acquires Genepharm, expands chronic disease portfolio

23-Apr-2019 By Vassia Barba

Jordan-based MS Pharma announces the acquisition of the Greek generic manufacturer Genepharm, aiming to add cardiovascular, CNS and oncology products to its portfolio.

Colorcon expands coating portfolio with DuPont’s Aquacoat

22-Apr-2019 By Vassia Barba

Colorcon adds DuPont’s Aquacoat technology, held in CR Alliance’s portfolio, whilst planning to transition existing customers over to the company.

BMS-Celgene mega-merger receives shareholder nod

15-Apr-2019 By Ben Hargreaves

The $74bn deal appeared to be fraying around edges, as certain shareholders voiced dissent, but a vote saw the deal pass with support from more than 75% of investors.

Novartis bets $1.6bn on inflammation-focused biotech

01-Apr-2019 By Ben Hargreaves

Novartis to acquire IFM Tre to gain access to one clinical and two pre-clinical assets, which are designed to combat chronic inflammatory conditions.

BMS investors voice discontent over $74bn Celgene deal

28-Feb-2019 By Ben Hargreaves

BMS has been struck a blow in its plans to acquire Celgene, after its largest investor questioned the risk of the deal.

Merck in $300m Immune Design boost for Keytruda

21-Feb-2019 By Ben Hargreaves

Announced today, the deal sees Merck pay $5.85 per share to acquire Immune Design and its portfolio of late-stage immunotherapies.

Lilly bets $8bn on genomic approach to cancer

07-Jan-2019 By Ben Hargreaves

Eli Lilly will acquire Loxo for $8bn to gain access to treatments that target cancers dependent on single gene abnormalities.

BMS begins year with $74bn Celgene acquisition

03-Jan-2019 By Ben Hargreaves

BMS announced that it will merge with Celgene, bolstering its oncology and immunology/inflammation franchises.

GSK and Pfizer JV creates ‘global leader in OTC products’

19-Dec-2018 By Flora Southey

Pfizer and GSK will combine their consumer healthcare companies in a joint venture – creating an OTC portfolio with 7.3% global market share.

Roquette buys majority stake in India-based excipient manufacturer

17-Dec-2018 By Maggie Lynch

Roquette has purchased a majority stake in excipient manufacturer Crest Cellose, in an aim to increase its footprint in India’s generic pharmaceutical market.